AllianceBernstein
KRYS icon

AllianceBernstein’s Krystal Biotech KRYS Stock Holding History

AllianceBernstein’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.79M Buy
34,039
+2,110
+7% +$630K ﹤0.01% 1256
2026
Q1 		$7.87M Buy
31,929
+400
+1% +$106K ﹤0.01% 1324
2025
Q4 		$7.77M Buy
31,529
+1,609
+5% +$339K ﹤0.01% 1343
2025
Q3 		$5.28M Sell
29,920
-1,200
-4% -$180K ﹤0.01% 1497
2025
Q2 		$4.28M Hold
31,120
– – ﹤0.01% 1544
2025
Q1 		$5.61M Hold
31,120
– – ﹤0.01% 1410
2024
Q4 		$4.88M Buy
31,120
+1,400
+5% +$248K ﹤0.01% 1499
2024
Q3 		$5.41M Hold
29,720
– – ﹤0.01% 1488
2024
Q2 		$5.46M Buy
29,720
+5,960
+25% +$1M ﹤0.01% 1456
2024
Q1 		$4.23M Sell
23,760
-2,140
-8% -$297K ﹤0.01% 1529
2023
Q4 		$3.21M Hold
25,900
– – ﹤0.01% 1696
2023
Q3 		$3M Sell
25,900
-200
-0.8% -$24.4K ﹤0.01% 1658
2023
Q2 		$3.06M Hold
26,100
– – ﹤0.01% 1663
2023
Q1 		$2.09M Hold
26,100
– – ﹤0.01% 1845
2022
Q4 		$2.07M Buy
26,100
+600
+2% +$44.5K ﹤0.01% 1900
2022
Q3 		$1.78M Hold
25,500
– – ﹤0.01% 1959
2022
Q2 		$1.67M Buy
25,500
+2,100
+9% +$131K ﹤0.01% 2055
2022
Q1 		$1.56M Buy
23,400
+2,700
+13% +$169K ﹤0.01% 2230
2021
Q4 		$1.45M Hold
20,700
– – ﹤0.01% 2321
2021
Q3 		$1.08M Hold
20,700
– – ﹤0.01% 2464
2021
Q2 		$1.41M Buy
20,700
+7,100
+52% +$496K ﹤0.01% 2379
2021
Q1 		$1.05M Buy
13,600
+300
+2% +$21.8K ﹤0.01% 2394
2020
Q4 		$798K Hold
13,300
– – ﹤0.01% 2398
2020
Q3 		$573K Sell
13,300
-700
-5% -$30.4K ﹤0.01% 2463
2020
Q2 		$580K Buy
14,000
+2,600
+23% +$125K ﹤0.01% 2509
2020
Q1 		$493K Sell
11,400
-600
-5% -$31.4K ﹤0.01% 2364
2019
Q4 		$665K Buy
12,000
+2,700
+29% +$132K ﹤0.01% 2431
2019
Q3 		$323K Buy
9,300
+1,200
+15% +$53.6K ﹤0.01% 2777
2019
Q2 		$326K Buy
+8,100
New +$265K ﹤0.01% 2795

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AllianceBernstein's KRYS Position: Q2 2026 in Review

AllianceBernstein increased its Krystal Biotech (KRYS) stake by 6.6% in Q2 2026, buying an estimated $630K and bringing the position to 34,039 shares worth $8.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

AllianceBernstein first reported a position in KRYS in Q2 2019 and has held it in 29 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • AllianceBernstein held 34,039 shares of Krystal Biotech worth $8.79M as of Q2 2026.
  • AllianceBernstein bought 2,110 Krystal Biotech shares in Q2 2026, an estimated $630K.
  • Krystal Biotech made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1256 holding.
  • AllianceBernstein first reported a position in Krystal Biotech in Q2 2019 and has held it in 29 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.